Revance Therapeutics - Stock Price History | RVNC
Historical daily share price chart and data for Revance Therapeutics since 2021 adjusted for splits. The latest closing stock price for Revance Therapeutics as of September 27, 2021 is 29.66.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
- The all-time high Revance Therapeutics stock closing price was 40.78 on November 11, 2015.
- The Revance Therapeutics 52-week high stock price is 33.83, which is 14.1% above the current share price.
- The Revance Therapeutics 52-week low stock price is 22.89, which is 22.8% below the current share price.
- The average Revance Therapeutics stock price for the last 52 weeks is 27.72.
|Revance Therapeutics Historical Annual Stock Price Data
||Average Stock Price
||Annual % Change
||Medical - Biomedical and Genetics
Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS? peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.